Merck KGaA Licenses CRISPR Gene-Editing Technology to Evotec

Date : 11/12/2019 @ 1:53PM
Source : Dow Jones News
Stock : Evotec SE (EVTCY)
Quote : 44.62  0.0 (0.00%) @ 9:13PM

Merck KGaA Licenses CRISPR Gene-Editing Technology to Evotec

Evotec SE (USOTC:EVTCY)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Evotec SE Charts.
   By Kim Richters 
 

Germany's Merck KGaA (MRK.XE) said Tuesday that it signed a licensing agreement to grant Evotec SE (EVT.XE) access to its CRISPR genome-editing technology.

The German biotechnology company will use Merck's gene-editing technology to research, test and develop new drugs, the company said.

The science and technology company didn't comment on financial terms of the deal.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

November 12, 2019 08:38 ET (13:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest EVTCY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.